Johnson Matthey, one of the global providers of advanced process technologies, and Rennovia Inc., a privately held company that develops novel catalysts and processes for the cost advantaged production of chemical products from renewable feedstocks, has announced that they have signed a license agreement with Archer Daniels Midland Company to provide catalyst and process technology for catalytic production of bio-based glucaric acid.
Jointly Developed License Process
The licensed process, jointly developed between Johnson Matthey and Rennovia, combines the efficiency and selectivity of heterogeneous catalytic process technology It uses renewable feedstocks to produce bio-based glucaric acid
Glucaric acid is an emerging platform chemical which has a wide range of applications in:
- Detergents and cleaners
- Concrete formulations
- Anti-corrosion markets
“We are proud to announce the licensing of this new and innovative technology to ADM, and we are excited about the future of this technology, which draws upon the fundamental process and catalyst development expertise within Johnson Matthey. This achievement also demonstrates the value of a strong collaborative approach, working together with Rennovia to commercialize a process for biobased chemicals.” said David Prest, Director of Business Development for Johnson Matthey’s Process Technologies Division.
Working Towards Commercialization of Glucaric Acid
“ADM continues to work toward commercialization of glucaric acid as a higher value product within our portfolio of bio-based performance chemicals,” said Kevin Moore, President of Renewable Chemicals for ADM. “We see a strong synergy in leveraging Rennovia’s breakthrough catalyst technology along with the process scale-up capabilities of Johnson Matthey to shorten the time frame needed to bring this new product to market for our customers.”
“We are delighted that ADM has decided to license glucaric acid technology from Rennovia and Johnson Matthey,” said Robert Wedinger, President and CEO of Rennovia. “It demonstrates the commitment of an industry leader and a key partner of Rennovia. We look forward to working even closer together to commercialize our innovative process for the production of cost advantaged glucaric acid.”